Hopes for Roche's taspoglutide falter on 12-18 month delay
This article was originally published in Scrip
Executive Summary
Roche has announced that it will probably delay filing its experimental GLP-1 analogue taspoglutide by 12-18 months due to increased incidence of hypersensitivity with the diabetes therapy. Taspoglutide had been due to be filed in 2011, but Roche told Scrip that that it is now unlikely to be submitted to regulators until 2012 or 2013.